Bharat Parenterals Q2 FY27 consolidated PAT at Rs 11.80 cr
For Q2 FY27, Bharat Parenterals reported consolidated total income of Rs 138.80 cr and PAT of Rs 11.80 cr, against Rs 68.20 cr and Rs (8.60) cr in Q2 FY26.
Key takeaways
- Revenue from operations Rs 136.30 cr in Q2 FY27 vs Rs 64.60 cr in Q2 FY26.
- Total income Rs 138.80 cr in Q2 FY27 vs Rs 68.20 cr in Q2 FY26.
- EBITDA Rs 23.60 cr in Q2 FY27 vs Rs 0.80 cr in Q2 FY26; margin 17.3% vs 1.3%.
- PAT Rs 11.80 cr in Q2 FY27 vs Rs (8.60) cr in Q2 FY26; margin 8.7% vs (13.3%).
- PAT to owners Rs 9.40 cr in Q2 FY27 vs Rs (7.20) cr in Q2 FY26.
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 136.30 cr | Rs 64.60 cr | +110.9% |
| PAT | Rs 11.80 cr | Rs (8.60) cr | n.m. |
| Margin | 17.3% | 1.3% | +1,603 bps |
As reported in the filing. Figures are transcribed, not computed.
• Basis: Consolidated statement of financial results, quarter ended 30-Sep-2026 vs quarter ended 30-Sep-2025 (Q2 FY27 vs Q2 FY26), as presented in the investor presentation’s group P&L table.
• Revenue from operations: Rs 136.30 cr in Q2 FY27 vs Rs 64.60 cr in Q2 FY26.
• Other income: Rs 2.50 cr in Q2 FY27 vs Rs 3.50 cr in Q2 FY26.
• Total income: Rs 138.80 cr in Q2 FY27 vs Rs 68.20 cr in Q2 FY26.
• EBITDA: Rs 23.60 cr in Q2 FY27 vs Rs 0.80 cr in Q2 FY26.
• EBITDA margin (%): 17.3% in Q2 FY27 vs 1.3% in Q2 FY26.
• PAT: Rs 11.80 cr in Q2 FY27 vs Rs (8.60) cr in Q2 FY26.
• PAT margin (%): 8.7% in Q2 FY27 vs (13.3%) in Q2 FY26.
• PAT to owners: Rs 9.40 cr in Q2 FY27 vs Rs (7.20) cr in Q2 FY26.
According to the group P&L table in the statement of financial results, consolidated revenue from operations for Bharat Parenterals Limited in Q2 FY27 was Rs 136.30 cr, compared with Rs 64.60 cr in the corresponding quarter a year earlier. Including other income of Rs 2.50 cr (Rs 3.50 cr in Q2 FY26), total income stood at Rs 138.80 cr versus Rs 68.20 cr in Q2 FY26.
On the cost side, the table shows total expenses implicitly through the reported EBITDA line. EBITDA for the quarter was Rs 23.60 cr, up from Rs 0.80 cr in Q2 FY26, with the EBITDA margin improving to 17.3% from 1.3% a year earlier, as per the EBITDA margin (%) row in the same table.
At the bottom line, the consolidated PAT line in the statement of financial results shows profit after tax of Rs 11.80 cr for Q2 FY27, compared with a loss of Rs (8.60) cr in Q2 FY26. The PAT margin (%) row records 8.7% for Q2 FY27 versus (13.3%) in the year-ago quarter. The table also discloses “PAT to owners” of Rs 9.40 cr in Q2 FY27, against Rs (7.20) cr in Q2 FY26, reflecting the share attributable to the company’s shareholders after non-controlling interest.
All figures above are taken directly from the consolidated group financial metrics P&L table in the statement of financial results within the investor presentation, for the quarter ended 30-Sep-2026 and the corresponding quarter ended 30-Sep-2025.
Track Bharat Parenterals Ltd
Cruxal reads every Bharat Parenterals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
